AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for … Read more
Market Cap & Net Worth: AIM ImmunoTech Inc (AIM)
AIM ImmunoTech Inc (NYSE MKT:AIM) has a market capitalization of $6.52 Million ($6.52 Million) as of March 18, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #30485 globally and #10046 in its home market, demonstrating a -25.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AIM ImmunoTech Inc's stock price $0.09 by its total outstanding shares 68754304 (68.75 Million).
AIM ImmunoTech Inc Market Cap History: 2015 to 2025
AIM ImmunoTech Inc's market capitalization history from 2015 to 2025. Data shows change from $2.90 Billion to $6.52 Million (-50.87% CAGR).
AIM ImmunoTech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AIM ImmunoTech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
80.08x
AIM ImmunoTech Inc's market cap is 80.08 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.90 Billion | $133.00K | -$15.23 Million | 21835.95x | N/A |
| 2016 | $2.09 Billion | $92.00K | -$7.50 Million | 22688.92x | N/A |
| 2017 | $1.06 Billion | $437.00K | -$8.26 Million | 2422.92x | N/A |
| 2018 | $544.53 Million | $367.00K | -$9.81 Million | 1483.74x | N/A |
| 2019 | $37.13 Million | $140.00K | -$10.83 Million | 265.20x | N/A |
| 2020 | $123.07 Million | $163.00K | -$16.26 Million | 755.03x | N/A |
| 2021 | $63.25 Million | $135.00K | -$21.51 Million | 468.55x | N/A |
| 2022 | $21.31 Million | $141.00K | -$21.09 Million | 151.16x | N/A |
| 2023 | $30.25 Million | $202.00K | -$28.96 Million | 149.76x | N/A |
| 2024 | $13.61 Million | $170.00K | -$17.32 Million | 80.08x | N/A |
Competitor Companies of AIM by Market Capitalization
Companies near AIM ImmunoTech Inc in the global market cap rankings as of March 18, 2026.
Key companies related to AIM ImmunoTech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
AIM ImmunoTech Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, AIM ImmunoTech Inc's market cap moved from $2.90 Billion to $ 6.52 Million, with a yearly change of -50.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $6.52 Million | -52.07% |
| 2024 | $13.61 Million | -55.00% |
| 2023 | $30.25 Million | +41.94% |
| 2022 | $21.31 Million | -66.30% |
| 2021 | $63.25 Million | -48.60% |
| 2020 | $123.07 Million | +231.48% |
| 2019 | $37.13 Million | -93.18% |
| 2018 | $544.53 Million | -48.57% |
| 2017 | $1.06 Billion | -49.28% |
| 2016 | $2.09 Billion | -28.12% |
| 2015 | $2.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AIM ImmunoTech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.52 Million USD |
| MoneyControl | $6.52 Million USD |
| MarketWatch | $6.52 Million USD |
| marketcap.company | $6.52 Million USD |
| Reuters | $6.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.